These cells were naïve to immune checkpoint inhibitors, and we examined whether the expression of key IFNγ downstream targets [PD-L1, PD-L2, nerve growth factor receptor (NGFR), HLA-A, -B, -C, and HLA-DR] could serve to assess the integrity of IFNγ signaling in melanoma. The gene discussed is NGFR; the disease is melanoma.